Prostatic Growth Rate Determined From Mri Data

Williams, Adrianne M.; Simon, Inpakala; Landis, Patricia; Moser, C; Christens-Barry, William A.; Carter, H. Ballentine; Metter, E. Jeffrey; Partin, Alan W.

doi:10.1097/00005392-199904020-00155

Cited by 22 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, the rate of growth was dependent on baseline prostate volume; the larger the prostate at baseline, the greater the percentage growth every year thereafter. Similar findings also were reported in men participating in the Baltimore Longitudinal Study of Aging [11,41]. Thus, although prostate volume is known to correlate poorly with symptoms and urinary flow at any given time, large prostate volume portends future clinical deterioration.…”

Section: Progressive Nature Of Benign Prostatic Hyperplasiasupporting

confidence: 76%

Use of 5α-reductase inhibitors to prevent benign prostatic hyperplasia disease

Marks¹

2006

Curr Urol Rep

View full text Add to dashboard Cite

A histologic change in the prostate, benign prostatic hyperplasia (BPH), is a normal part of aging. However, BPH disease, defined here as a life-altering urinary condition caused by BPH requiring prompt medical intervention, is a serious medical disorder associated with major complications, surgical intervention, and severe lifestyle interference. BPH disease is preventable. The rationale for BPH disease prevention rests on four pillars of evidence: (1) BPH disease generally is a progressive disorder; (2) complications and severe lifestyle interference from BPH disease are common and serious; (3) men at greatest risk of BPH disease can be identified using prostate-specific antigen (PSA) level higher than 1.5 ng/mL as a surrogate marker for an enlarged prostate; and (4) 5alpha-reductase inhibitors (5ARIs) reduce the primary androgen responsible for prostate growth (dihydrotestosterone), shrink the prostate, and arrest the disease process regardless of symptom status. Thus, we now can identify men with an enlarged prostate at risk for BPH disease who may be candidates for preventive therapy with 5ARIs, regardless of urinary symptoms or bother.

show abstract

Section: Progressive Nature Of Benign Prostatic Hyperplasiasupporting

confidence: 76%

Use of 5α-reductase inhibitors to prevent benign prostatic hyperplasia disease

Marks¹

2006

Curr Urol Rep

View full text Add to dashboard Cite

show abstract

“…Regarding the prostate, all groups showed increases in prostate volume that were greater than those observed previously in prospective studies of older men (31,32). The change in ultrasound equipment between baseline and the end of the study may have contributed to the seemingly larger-than-expected magnitude of volume change between baseline and end-of-study.…”

Section: Discussionmentioning

confidence: 47%

Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone

Amory

Watts

Easley

et al. 2004

The Journal of Clinical Endocrinology & Metabolism

440

252

View full text Add to dashboard Cite

Older men, particularly those with low serum testosterone (T) levels, might benefit from T therapy to improve bone mineral density (BMD) and reduce fracture risk. Concerns exist, however, about the impact of T therapy on the prostate in older men. We hypothesized that the combination of T and finasteride (F), a 5 alpha-reductase inhibitor, might increase BMD in older men without adverse effects on the prostate. Seventy men aged 65 yr or older, with a serum T less than 12.1 nmol/liter on two occasions, were randomly assigned to receive one of three regimens for 36 months: T enanthate, 200 mg im every 2 wk with placebo pills daily (T-only); T enanthate, 200 mg every 2 wk with 5 mg F daily (T+F); or placebo injections and pills (placebo). Low BMD was not an inclusion criterion. We obtained serial measurements of BMD of the lumbar spine and hip by dual x-ray absorptiometry. Prostate-specific antigen (PSA) and prostate size were measured at baseline and during treatment to assess the impact of therapy on the prostate. Fifty men completed the 36-month protocol. By an intent-to-treat analysis including all men for as long as they contributed data, T therapy for 36 months increased BMD in these men at the lumbar spine [10.2 +/- 1.4% (mean percentage increase from baseline +/- SEM; T-only) and 9.3 +/- 1.4% (T+F) vs. 1.3 +/- 1.4% for placebo (P < 0.001)] and in the hip [2.7 +/- 0.7% (T-only) and 2.2 +/- 0.7% (T+F) vs. -0.2 +/- 0.7% for placebo, (P < or = 0.02)]. Significant increases in BMD were seen also in the intertrochanteric and trochanteric regions of the hip. After 6 months of therapy, urinary deoxypyridinoline (a bone-resorption marker) decreased significantly compared with baseline in both the T-only and T+F groups (P < 0.001) but was not significantly reduced compared with the placebo group. Over 36 months, PSA increased significantly from baseline in the T-only group (P < 0.001). Prostate volume increased in all groups during the 36-month treatment period, but this increase was significantly less in the T+F group compared with both the T-only and placebo groups (P = 0.02). These results demonstrate that T therapy in older men with low serum T increases vertebral and hip BMD over 36 months, both when administered alone and when combined with F. This finding suggests that dihydrotestosterone is not essential for the beneficial effects of T on BMD in men. In addition, the concomitant administration of F with T appears to attenuate the impact of T therapy on prostate size and PSA and might reduce the chance of benign prostatic hypertrophy or other prostate-related complications in older men on T therapy. These findings have important implications for the prevention and treatment of osteoporosis in older men with low T levels.

show abstract

“…6 Using MRI instead our research group previously reported on age related prostate volume changes in 64 community men from the Baltimore Longitudinal Study of Aging. 7 In these men the overall prostate growth rate was 2.36 cc per year. In this study we expand on these findings and further examine longitudinal changes in prostate volume in a larger population of community men from the BLSA.…”

mentioning

confidence: 85%

“…Since then approximately 1,806 males have enrolled, primarily residents of Maryland or Washington, D. C. As part of the study protocol participants undergo a comprehensive medical, physical and neuropsychological evaluation every 2 years as previously described. 7,8 All BLSA subjects provided informed consent, and the study protocol was approved by the institutional review boards of MedStar and the Johns Hopkins Medical Institutions (Baltimore, Maryland).…”

Section: Methodsmentioning

confidence: 99%

Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging

et al. 2009

Self Cite

View full text Add to dashboard Cite

Purpose According to a 1944 publication by Swyer benign prostatic hyperplasia develops in some men after age 45 with further prostatic growth whereas in other men prostate size remains stable or decreases with advancing age. Although there is an abundance of literature describing prostatic enlargement in association with benign prostatic hyperplasia, less is known about the phenomenon of prostate atrophy. Materials and Methods In the Baltimore Longitudinal Study of Aging serial pelvic magnetic resonance imaging was performed in men without prostate cancer beginning in 1993. From this population we retrospectively identified 278 men with 2 or more magnetic resonance imaging determined prostate volume measurements to examine differential growth rates in a cohort of community men over time. Results Median age was 58 years and median prostate size was 28 cc at study entry. At a median followup of 4.3 years prostate size increased in 61.9% and remained stable or decreased in 38.1% of men. The median rate of volume change was 0.6 cc per year (range −9.9 to 62.1), corresponding to a median growth rate of 2.5% per year (range −29.2 to 176.4%). During followup 64.6% of men with an initial prostate size less than 40 cc had prostate growth compared to only 50.9% of men with an initial prostate size of 40 cc or greater. Conclusions These results suggest that changes in prostate size are highly variable among aging men. Although benign prostatic hyperplasia is common, a considerable proportion of aging men have a stable or decreasing prostate size. Further research is needed to identify the underlying mechanism for such differences in prostate growth.

show abstract

Prostatic Growth Rate Determined From Mri Data

Cited by 22 publications

References 0 publications

Use of 5α-reductase inhibitors to prevent benign prostatic hyperplasia disease

Use of 5α-reductase inhibitors to prevent benign prostatic hyperplasia disease

Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone

Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging

Contact Info

Product

Resources

About